MaxCyte, Inc.
MXCT
$2.04
-$0.02-0.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.39M | 8.69M | 8.16M | 10.43M | 11.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.39M | 8.69M | 8.16M | 10.43M | 11.34M |
| Cost of Revenue | 1.50M | 2.28M | 1.93M | 1.49M | 1.40M |
| Gross Profit | 8.89M | 6.41M | 6.24M | 8.94M | 9.94M |
| SG&A Expenses | 14.22M | 13.68M | 13.95M | 14.26M | 14.47M |
| Depreciation & Amortization | 1.06M | 1.02M | 1.02M | 1.03M | 1.07M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.69M | 21.59M | 22.22M | 22.40M | 23.62M |
| Operating Income | -12.30M | -12.90M | -14.05M | -11.97M | -12.28M |
| Income Before Tax | -10.26M | -10.60M | -11.56M | -9.38M | -9.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.26M | -10.60M | -11.56M | -9.38M | -9.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.26M | -10.60M | -11.56M | -9.38M | -9.53M |
| EBIT | -12.30M | -12.90M | -14.05M | -11.97M | -12.28M |
| EBITDA | -11.20M | -11.84M | -12.99M | -10.89M | -11.16M |
| EPS Basic | -0.10 | -0.10 | -0.11 | -0.09 | -0.09 |
| Normalized Basic EPS | -0.06 | -0.06 | -0.07 | -0.06 | -0.06 |
| EPS Diluted | -0.10 | -0.10 | -0.11 | -0.09 | -0.09 |
| Normalized Diluted EPS | -0.06 | -0.06 | -0.07 | -0.06 | -0.06 |
| Average Basic Shares Outstanding | 105.95M | 105.55M | 105.11M | 104.64M | 104.09M |
| Average Diluted Shares Outstanding | 105.95M | 105.55M | 105.11M | 104.64M | 104.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |